The human gut microbiota comprises of a complex and diverse array of microorganisms,and over the years the interaction between human diseases and the gut microbiota has become a subject of growing interest.Disturbed m...The human gut microbiota comprises of a complex and diverse array of microorganisms,and over the years the interaction between human diseases and the gut microbiota has become a subject of growing interest.Disturbed microbial milieu in the gastrointestinal tract is central to the pathogenesis of several diseases including antibiotic-associated diarrhea and Clostridioides difficile infection(CDI).Manipulation of this microbial milieu to restore balance by microbial replacement therapies has proven to be a safe and effective treatment for recurrent CDI.There is considerable heterogeneity in various aspects of stool processing and administration for fecal microbiota transplantation(FMT)across different centers globally,and standardized microbioal replacement therapies offer an attractive alternative.The adverse effects associated with FMT are usually mild.However,there is paucity of data on long term safety of FMT and there is a need for further studies in this regard.With our increasing understanding of the host-microbiome interaction,there is immense potential for microbial replacement therapies to emerge as a treatment option for several diseases.The role of microbioal replacement therapies in diseases other than CDI is being extensively studied in ongoing clinical trials and it may be a potential treatment option for inflammatory bowel disease,irritable bowel syndrome,obesity,multidrug resistant infections,and neuropsychiatric illnesses.Fecal microbiota transplantation for non-CDI disease states should currently be limited only to research settings.展开更多
Fecal microbiota transplantation(FMT)has emerged as an effective treatment for recurrent Clostridioides difficile infection(CDI)and is recommended as a standard of care(1).Since the first randomized clinical trial pub...Fecal microbiota transplantation(FMT)has emerged as an effective treatment for recurrent Clostridioides difficile infection(CDI)and is recommended as a standard of care(1).Since the first randomized clinical trial published in 2013,there has been an exponential rise in the number of FMTs being performed(2).However,access to FMT varies according to location and type of healthcare establishment and is complicated by the regulatory issues surrounding its use(3,4).Storing and banking stool may be an accessible and economical option for patients requiring FMT,considering the costs associated with donor screening,stool processing and storage by individual providers(5).展开更多
文摘The human gut microbiota comprises of a complex and diverse array of microorganisms,and over the years the interaction between human diseases and the gut microbiota has become a subject of growing interest.Disturbed microbial milieu in the gastrointestinal tract is central to the pathogenesis of several diseases including antibiotic-associated diarrhea and Clostridioides difficile infection(CDI).Manipulation of this microbial milieu to restore balance by microbial replacement therapies has proven to be a safe and effective treatment for recurrent CDI.There is considerable heterogeneity in various aspects of stool processing and administration for fecal microbiota transplantation(FMT)across different centers globally,and standardized microbioal replacement therapies offer an attractive alternative.The adverse effects associated with FMT are usually mild.However,there is paucity of data on long term safety of FMT and there is a need for further studies in this regard.With our increasing understanding of the host-microbiome interaction,there is immense potential for microbial replacement therapies to emerge as a treatment option for several diseases.The role of microbioal replacement therapies in diseases other than CDI is being extensively studied in ongoing clinical trials and it may be a potential treatment option for inflammatory bowel disease,irritable bowel syndrome,obesity,multidrug resistant infections,and neuropsychiatric illnesses.Fecal microbiota transplantation for non-CDI disease states should currently be limited only to research settings.
文摘Fecal microbiota transplantation(FMT)has emerged as an effective treatment for recurrent Clostridioides difficile infection(CDI)and is recommended as a standard of care(1).Since the first randomized clinical trial published in 2013,there has been an exponential rise in the number of FMTs being performed(2).However,access to FMT varies according to location and type of healthcare establishment and is complicated by the regulatory issues surrounding its use(3,4).Storing and banking stool may be an accessible and economical option for patients requiring FMT,considering the costs associated with donor screening,stool processing and storage by individual providers(5).
